Corporate history
RELTEC was established in 1993 by founder Noboru Horiguchi as a research and development-oriented medical device manufacturer. RELTEC’s main product, a highly unique medical device for professionals (RE therapeutic device – a negative potential therapeutic device with the transcutaneous electron supply function to the human body), has been well received by customers, and RELTEC has steadily grown. In the fiscal year ending March 2007, RELTEC posted sales of approximately 1.9 billion JPY; in the fiscal year ending March 2007, it posted an operating income of approximately 250 million JPY.
RE therapeutic devices were generally purchased by patients with chronic diseases who wanted more than the standard of care for complementary and alternative medicine. They were used for home therapy under the direction of a doctor. On the other hand, the founder wanted to advance clinical development for various diseases that customers suffer from, obtain official indications for those diseases, and thereby position RE therapeutic devices as one of the standards of care. This is because the current official indications for the RE therapeutic device are only headaches, stiff shoulders, insomnia, and chronic constipation, and these indications are often different from the diseases that customers are treating with the RE therapeutic device. The founder also believed that the RE therapeutic device’s diverse action characteristics made it suitable for maintaining and promoting health.
As mentioned above, the founder has always wanted to contribute to the health of many people by popularizing RE therapeutic devices as a standard of care and a means of maintaining and promoting health. Therefore, with the backing of popular products and firm performance, the founder used borrowings as the primary source of funding to expand the business, including through clinical development overseas, the construction of new factories and the establishment of sales subsidiaries in Japan, and the establishment of production and sales subsidiaries in China. However, due to a lack of funds, these projects could not be completed, and RELTEC ended up with debts of approximately 6.5 billion yen, making it difficult to continue its business.
To reorganize a large amount of debt, RELTEC proceeded with legal debt reorganization and cleared its debts in March 2021. However, sales plummeted due to the reputation associated with the bankruptcy, and with the addition of the impact of the COVID-19 pandemic, business performance has been sluggish in recent years.
RELTEC has conducted four clinical studies overseas using the RE therapeutic device (United States: chronic hepatitis C (unpublished), China: HIV infection/AIDS1, metabolic syndrome2 and lactate metabolism3), all of which have produced favorable outcomes.
By leveraging the outcomes of these clinical studies and our many years of know-how in developing and manufacturing medical devices for professionals, RELTC is working to position the RE therapeutic device as the standard of care and a means of maintaining and promoting health.
Management philosophy
MIssion
Contribute to people’s health by exploring and utilizing reducing electronic technology
Values
1. Fairness and transparency for all stakeholders
2. High discipline
3. Management that prioritizes sustainability
4. Proactive and independent thinking and action in response to changes in the business environment
- Antibiotics & Chemotherapy. 2008; 24(10): 93-103. ↩︎
- Research Society of Electron Immunotherapy. 2022; 8(1): 20-9. ↩︎
- Research Society of Electron Immunotherapy. 2024; 10(1): 3-6. ↩︎
Vision
RELTEC is a single business company solely engaged in developing, manufacturing, and selling medical devices and related products. Therefore, RELTEC plans to state our vision on the business page that will be created.